|
KMID : 0355820230440010049
|
|
Korean Journal of Oral Anatomy
2023 Volume.44 No. 1 p.49 ~ p.58
|
|
|
The Anticancer Activity Effects of Tivozanib in OSCC Cell Lines
|
|
Kang Hae-Mi
Lee Jong-Won
Kim In-Ryoung
Park Bong-Soo
|
|
|
Abstract
|
|
|
|
Tivozanib is a tyrosine kinase inhibitor (TKI) used in the treatment of renal cell carcinoma. It targets vascular endothelial growth factor receptors (VEGFRs) within the tumor, inhibiting the blood supply to the tumor, which in turn, suppresses the growth and spread of cancer cells. While there have been numerous reports highlighting the association between diseases in the kidneys and Tivozanib, its pharmacological effects on oral cancer remain largely unexplored. Therefore, this study aimed to investigate the relationship between Tivozanib and the mechanisms related to cancer cell death (apoptosis) and autophagy in Ca9-22 and CAL-27 oral squamous cell carcinoma cell lines. The objective was to demonstrate an increased efficacy in treating oral cancer cells. The results showed that Tivozanib effectively exhibited its anti-cancer activity by regulating the expression of proteins associated with intrinsic cell apoptotic pathways and early autophagy in Ca9-22 and CAL-27 cells.
|
|
|
KEYWORD
|
|
|
Anticancer, Apoptosis, Autophagy, OSCC, Tivozanib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|